IN2009CN03372A - - Google Patents

Download PDF

Info

Publication number
IN2009CN03372A
IN2009CN03372A IN3372CHN2009A IN2009CN03372A IN 2009CN03372 A IN2009CN03372 A IN 2009CN03372A IN 3372CHN2009 A IN3372CHN2009 A IN 3372CHN2009A IN 2009CN03372 A IN2009CN03372 A IN 2009CN03372A
Authority
IN
India
Prior art keywords
protein
canine
tslp
peptide fragments
canine tslp
Prior art date
Application number
Other languages
English (en)
Inventor
Jeanine D Mattson
Daniel M Gorman
Waal Malefyt Rene De
Mohamad A Morsey
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of IN2009CN03372A publication Critical patent/IN2009CN03372A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43—Sweetening agents, e.g. thaumatin, monellin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN3372CHN2009 2006-12-14 2007-12-11 IN2009CN03372A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87513506P 2006-12-14 2006-12-14
PCT/US2007/025318 WO2008076255A2 (fr) 2006-12-14 2007-12-11 Lymphopoïétine stromale thymique (tslp) canine et utilisations associées

Publications (1)

Publication Number Publication Date
IN2009CN03372A true IN2009CN03372A (fr) 2015-08-07

Family

ID=39430681

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3372CHN2009 IN2009CN03372A (fr) 2006-12-14 2007-12-11

Country Status (18)

Country Link
US (3) US7718772B2 (fr)
EP (1) EP2104683B1 (fr)
JP (4) JP2010512744A (fr)
KR (1) KR101525631B1 (fr)
CN (2) CN102584998B (fr)
AU (1) AU2007334531B2 (fr)
BR (1) BRPI0720001A2 (fr)
CA (1) CA2671865C (fr)
CO (1) CO6210756A2 (fr)
ES (1) ES2582655T3 (fr)
IL (2) IL199170A (fr)
IN (1) IN2009CN03372A (fr)
MX (1) MX2009006470A (fr)
NZ (1) NZ578352A (fr)
RU (2) RU2457217C2 (fr)
UA (3) UA120027C2 (fr)
WO (1) WO2008076255A2 (fr)
ZA (1) ZA200904152B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718772B2 (en) * 2006-12-14 2010-05-18 Schering-Plough Animal Health Corporation Canine thymic stromal lymphopoietin protein and uses thereof
JP5492158B2 (ja) 2011-08-24 2014-05-14 富士フイルム株式会社 ヒトｔｓｈ及び犬ｔｓｈに対する抗体
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
AR090915A1 (es) 2012-05-04 2014-12-17 Intervet Int Bv Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg
EP2981280A2 (fr) * 2013-04-04 2016-02-10 IEO - Istituto Europeo di Oncologia Srl Fragments de lymphopoïétine stromale thymique et utilisations associées
LT3031913T (lt) * 2013-08-09 2019-05-27 Astellas Pharma Inc. Naujas antikūnas, atpažįstantis žmogaus tslp receptorių
EP4124624A3 (fr) 2013-12-20 2023-05-03 Intervet International B.V. Anticorps contre le pd-1 canin
WO2015118124A1 (fr) * 2014-02-06 2015-08-13 Vib Vzw Antagoniste du récepteur de la lymphopoïétine stromale thymique
JP6938383B2 (ja) 2015-04-02 2021-09-22 インターベット インターナショナル ベー． フェー． イヌインターロイキン４受容体アルファに対する抗体
KR20180042433A (ko) 2015-09-09 2018-04-25 노파르티스 아게 흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
CA3005696A1 (fr) 2015-12-18 2017-06-22 Intervet International B.V. Anticorps humains caninises diriges contre l'il-4r alpha humaine et canine
EP3538558A4 (fr) 2016-11-09 2020-07-15 North Carolina State University Traitement de maladies allergiques au moyen d'une protéine chimérique
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
CN115028722B (zh) * 2021-03-05 2024-09-03 拜西欧斯（北京）生物技术有限公司 抗tslp抗体及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5413914A (en) * 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
ES2288036T5 (es) * 1998-11-13 2017-07-06 Immunex Corporation ADN de TSLP humano y polipéptidos
AU2396600A (en) 1998-12-30 2000-07-31 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
WO2002000724A2 (fr) * 2000-06-28 2002-01-03 Amgen, Inc. Molecules de recepteur de lymphopoietine de stroma thymique et utilisations de celles-ci
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
CA2532595A1 (fr) * 2003-07-18 2005-01-27 Schering Corporation Traitement et diagnostic de neoplasmes au moyen de la lymphopoietine stromale thymique
WO2006023226A2 (fr) * 2004-07-28 2006-03-02 Tanox, Inc. Promoteur de lymphopoietine stromale thymique et son utilisation
SE532251C2 (sv) 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
US7718772B2 (en) 2006-12-14 2010-05-18 Schering-Plough Animal Health Corporation Canine thymic stromal lymphopoietin protein and uses thereof

Also Published As

Publication number Publication date
KR101525631B1 (ko) 2015-06-04
WO2008076255A2 (fr) 2008-06-26
US20080152620A1 (en) 2008-06-26
JP2010512744A (ja) 2010-04-30
JP2012090647A (ja) 2012-05-17
RU2012113162A (ru) 2013-10-20
UA120027C2 (uk) 2019-09-25
RU2457217C2 (ru) 2012-07-27
MX2009006470A (es) 2009-06-26
UA108064C2 (uk) 2015-03-25
RU2617957C2 (ru) 2017-04-28
US8076456B2 (en) 2011-12-13
UA95329C2 (ru) 2011-07-25
US20130183291A1 (en) 2013-07-18
CA2671865C (fr) 2017-01-10
US20110033478A1 (en) 2011-02-10
IL199170A (en) 2015-04-30
CA2671865A1 (fr) 2008-06-26
AU2007334531B2 (en) 2012-04-12
CN101631800A (zh) 2010-01-20
NZ578352A (en) 2012-05-25
CN102584998A (zh) 2012-07-18
BRPI0720001A2 (pt) 2013-12-24
EP2104683A2 (fr) 2009-09-30
AU2007334531A1 (en) 2008-06-26
JP2013048637A (ja) 2013-03-14
CN101631800B (zh) 2012-12-05
KR20090097921A (ko) 2009-09-16
ES2582655T3 (es) 2016-09-14
US8791242B2 (en) 2014-07-29
JP5707380B2 (ja) 2015-04-30
US7718772B2 (en) 2010-05-18
EP2104683B1 (fr) 2016-05-25
ZA200904152B (en) 2011-11-30
IL215507A0 (en) 2011-11-30
CO6210756A2 (es) 2010-10-20
JP2015107121A (ja) 2015-06-11
JP6117767B2 (ja) 2017-04-19
RU2009126617A (ru) 2011-01-20
CN102584998B (zh) 2017-07-04
WO2008076255A3 (fr) 2008-09-18

Similar Documents

Publication Publication Date Title
MX2009006470A (es) Proteina linfopoyetina estromatica timica de canino, y usos de la misma.
JO3351B1 (ar) بروتينات رابطة مستضِدة قادرة على ربط مكونات ليمفاوية سدوية سُعترية الشكل
MX359903B (es) Proteínas estructurales de una mutación del parvovirus como vacunas.
WO2011032161A3 (fr) Vaccins dirigés contre les cellules de langerhans
MY162752A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2007106476A3 (fr) Compositions et procédés pour renforcer l'immunogénicité d'antigènes
NZ577828A (en) Human antibodies that bind human il-12 and methods for producing
WO2010104747A3 (fr) Vaccins ciblés vers des cellules présentant des antigènes
WO2005066204A3 (fr) Vaccin stimulant la croissance a base d'un epitope neutralisant
WO2010104761A3 (fr) Anticorps anti-cd40 et utilisations de ceux-ci
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
WO2008005880A3 (fr) Anticorps anti-norovirus
WO2005120565A8 (fr) Vaccins contre le sras et procedes de production d'anticorps tres puissants
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
WO2008098917A3 (fr) Nouveaux anticorps
WO2008130382A3 (fr) Protéines de fusion à base de cytokine pour le traitement de troubles immunitaires
MX2010001237A (es) Nuevos anticuerpos.
WO2006124451A3 (fr) Anticorps anti-il-13, compositions, procedes et utilisations
WO2008118487A3 (fr) Compositions et procédés pour augmenter l'immunogénicité de vaccins à base de glycoprotéine
WO2007050095A3 (fr) Vaccins améliorés et leurs procédés d'utilisation
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.
WO2007127372A3 (fr) Adjuvants génétiques pour vaccins viraux
MX2009011851A (es) Plasmidos de dna que tienen expresion y estabilidad mejoradas.
UA100531C2 (ru) Антитело, которое специфически связывается с тимическим стромальным лимфопоэтином (tslp)
AU2005292852A8 (en) Method of immunizing animal, composition for immunization, method of producing antibody, method of producing hybridoma and method of producing monoclonal antibody